Key Updates in Non-Metastatic and Metastatic Prostate Cancer Treatment : Episode 21

Practical Application of PARP Inhibitors in Metastatic CRPC

May 24, 2023

Alan H. Bryce, MD, Mayo Clinic
Elisabeth I. Heath, MD, FACP, Karmanos Cancer Institute

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

EP: 1.Breakthroughs in Imaging Modalities for Prostate Cancer

EP: 2.Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps

EP: 3.Recent Progress in the Prostate Cancer Treatment Landscape

EP: 4.Key Unmet Needs in Prostate Cancer Management

EP: 5.Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer

EP: 6.nmCRPC: Clinical Trial Data on AR Inhibitors

EP: 7.AR Inhibitors in nmCRPC: Real-World Data

EP: 8.Importance of Quality of Life When Choosing Therapy for nmCRPC

EP: 9.Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

EP: 10.Optimizing Care for Patients With Non-metastatic CRPC

EP: 11.Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

EP: 12.Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

EP: 13.mHSPC: Use of Triplet Therapy

EP: 14.Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

EP: 15.Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES

EP: 16.Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1

EP: 17.Educating Patients on Treatment Options in Metastatic HSPC

EP: 18.Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

EP: 19.Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

EP: 20.Metastatic CRPC: Advent of PARP Inhibitors

EP: 21.Practical Application of PARP Inhibitors in Metastatic CRPC

EP: 22.IO Therapy in mCRPC and Clinical Pearls

Related Videos

Yuan Yuan, MD, PhD

Jeffery Zonder, MD

David R. Wise, MD, PhD

Andrew J. Armstrong, MD, MSc

Benjamin V. Stone, MD

Scott Tagawa, MD, MS, FACP

Expert on RCC

Experts on DTC

Experts on DTC

Expert on RCC

Related Content

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

Related Content

The FDA has approved olaparib (Lynparza) plus abiraterone and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

Michael C. Haffner, MD, PhD

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

Morie A. Gertz, MD

Birtamimab Under Investigation in Mayo Stage IV AL Amyloidosis

USC Norris Comprehensive Cancer Center, UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Fox Chase Cancer Center, the University of Chicago Comprehensive Cancer Center

Stand Up to Cancer Grant Recipients Discuss Initiative to Expand Access to Early-Phase Clinical Trials

Lida A. Mina, MD

Genomic Testing Is Critical for Improved Personalized Medicine and Treatment Sequencing in Breast Cancer

Benjamin H. Lowentritt, MD, FACS

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

Latest Conference Coverage

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.